Ligand Pharmaceuticals Incorporated (LGNDZ)

OTCMKTS · Delayed Price · Currency is USD · Rights
0.0016
0.00 (0.00%)
At close: Apr 14, 2026
Market Cap4.00B +78.9%
Revenue (ttm)268.09M +60.4%
Net Income124.45M
EPS6.13
Shares Outn/a
PE Ratio32.10
Forward PE21.17
Dividendn/a
Ex-Dividend Daten/a
Volume100,000
Average Volume124,628
Open0.0016
Previous Closen/a
Day's Range0.0016 - 0.0016
52-Week Range0.0013 - 0.0129
Betan/a
RSI36.64
Earnings DateMay 7, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteopor... [Read more]

Industry Pharmaceutical Preparations
Sector Healthcare
Founded 1987
Employees 47
Stock Exchange OTCMKTS
Ticker Symbol LGNDZ